Connect with us

Business

Hemas Pharmaceuticals Launch Renowned ‘Seven Seas – Pulse Original’ in Sri Lankan Market

Published

on

Hemas Pharma team introducing ‘Seven Seas - Pulse Original’ to modern trade networks.

Hemas Pharmaceuticals, one of the leading pharmaceutical companies and the sole authorized agent in Sri Lanka for world renowned ‘Seven Seas’ fish oil brand, recently launched ‘Seven Seas – Pulse Original’ fish oil product in the Sri Lankan market. ‘Seven Seas’ is one of the most popular fish oil brands in the world marketed across 60 countries and ‘Pulse Original’ is a key product in the ‘Seven Seas’ portfolio, designed for general health and wellness of adults.

Commenting on the launch of ‘Seven Seas – Pulse Original’ in Sri Lanka, Janaka Prasanna, Senior Business Manager of ‘Seven Seas’ said ‘‘We are proud to include ‘Seven Seas – Pulse Original’ in our wide portfolio of world class products. Most importantly we feel this is a timely introduction in terms of supporting the overall health and wellbeing of Sri Lankans. As times get tougher, we naturally tend to neglect our health and that’s where a proven nutritional supplement like ‘Pulse Original’ comes into play’’.

‘‘As a leading supplementary brand in the country, we operate one of the most well-established distribution networks and we earnestly look forward to taking the benefits of this product to all Sri Lankans across the country’’ Prasanna further added.

Fish oil is a trusted dietary source of Omega-3 fatty acids that are necessary for the formation of new cells and for many other bodily processes. Its long list of benefits include supporting immunity, supporting bone and joint health, supporting heart health, and helping to maintain healthy skin in adults.

‘Seven Seas’, a part of Procter & Gamble Health, has a history of over 85 years in developing and manufacturing Cod Liver/Fish oil nutrient supplements and its trusted products serve people across over 60 countries across the globe.

With Hemas Pharmaceuticals managing ‘Seven Seas’ distribution in Sri Lanka, their trusted product line is now available to all Sri Lankans around the country.

A fully owned subsidiary of Hemas Holdings PLC, Hemas Pharmaceuticals is a leading importer and distributor of pharmaceutical, surgical and diagnostics, consumer health and animal health products in Sri Lanka. As a market leader, Hemas Pharmaceuticals counts over 80 years of operation, changing Sri Lanka’s healthcare sector through constant innovation and the creation of the most comprehensive distribution network in the country. The Company provides Distribution, Marketing and Channel solutions for a wide portfolio of reputed global brands and partners.



Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

SL confronting ‘decisive test of fiscal discipline’

Published

on

Ranjith Keerthi Tennakoon

Sri Lanka enters the new year confronting a familiar but deepening economic strain, with falling foreign reserves, a weakening rupee, rising public debt and mounting disaster-related losses posing what analysts describe as a decisive test of fiscal discipline and policy coherence.

Sri Lanka Human Rights Centre Executive Director and former Provincial Governor Ranjith Keerthi Tennakoon has warned that the country urgently requires a coordinated economic response to prevent further deterioration, particularly as the cost of post-disaster reconstruction threatens to exert fresh pressure on already strained public finances.

“While the government has succeeded in revenue augmentation through heavy taxation and repeated increases in electricity and gas tariffs, its performance in maintaining fiscal discipline remains weak,” Tennakoon said in an economic indicators statement issued on January 5.

According to figures cited by Tennakoon, Sri Lanka’s domestic debt stood at Rs. 17,595.05 billion when President Anura Kumara Dissanayake assumed office. By the end of September 2025, that figure had climbed to Rs. 18,701.46 billion, reflecting an increase of Rs. 1,106.41 billion within a year.

External debt has also trended upward. From Rs. 10,429.04 billion at the end of 2024, foreign debt rose to Rs. 10,974.34 billion by September 2025. As a result, Sri Lanka’s total public debt stock now stands at Rs. 29,675.81 billion, underscoring the scale of the country’s fiscal exposure.

“This trajectory raises serious concerns about long-term debt sustainability,” Tennakoon warned, noting that debt servicing costs will intensify further if currency depreciation continues.

Foreign reserves under pressure

The steady decline in foreign reserves remains one of the most critical challenges facing the economy. Gross official reserves fell from USD 6,531 million in March 2025 to USD 6,033 million by the end of November, a contraction of nearly USD 500 million.

Tennakoon cautioned that upcoming reconstruction needs following widespread floods and landslides will necessitate substantial imports of construction materials, machinery and industrial inputs, inevitably drawing down scarce foreign exchange reserves.

Although Sri Lanka managed to maintain a current account surplus in 2024, the balance slipped back into deficit during September and October 2025, before returning to surplus in November. While a surplus is not required at all times, Tennakoon said the November turnaround offered a “cautious but positive signal” regarding the economy’s direction.

The rupee’s depreciation continues to amplify macroeconomic risks. The exchange rate has weakened from Rs. 293.25 per US dollar last year to around Rs. 309.45, increasing the rupee cost of foreign debt servicing while driving up import and production costs.

More troubling, Tennakoon noted, is the widening gap between commercial bank exchange rates and the informal undiyal (black market) rate, reflecting growing uncertainty and eroding confidence.

“This was precisely how the 2021–2022 economic crisis began — with a widening divergence between official and informal exchange rates,” he warned.

The economic fallout from recent floods and landslides adds another layer of urgency. Tennakoon criticised the government for failing, thus far, to prepare a comprehensive estimate of financial losses and reconstruction costs.

Preliminary assessments by the World Bank estimate disaster-related losses at USD 4 billion, while the International Labour Organization (ILO) places the figure as high as USD 16 billion, equivalent to 16 percent of GDP.

“Massive tax resources will be required for relief payments, while reconstruction will demand substantial foreign exchange for imports,” Tennakoon said, stressing that the government must urgently prepare credible financial assessments to mobilise both domestic and international support.

He also warned that delays in providing adequate relief have already become a serious concern for displaced communities struggling to rebuild their lives.

By Ifham Nizam

Continue Reading

Business

Driving Growth: SEC and CSE collaborate to expedite listings

Published

on

The Securities and Exchange Commission of Sri Lanka (SEC) in collaboration with the Colombo Stock Exchange (CSE) conducted an awareness session for Corporate Finance Advisors focusing on enhancing regulatory compliance and streamlining the listing process.

The forum brought together Corporate Finance Advisors and senior officials from the SEC and CSE to enhance the listing process by addressing regulatory expectations, identifying prevalent shortcomings in applications, and establishing best practices to strengthen investor confidence and market integrity.

Addressing the participants, Senior Prof. D.B.P.H. Dissabandara, Chairman, SEC highlighted the vital role Corporate Finance Advisors play in building market confidence beyond their traditional functions in facilitating listings, mergers, and acquisitions.

“Your screening process, your due diligence supports market confidence directly in addition to your key major roles,” the Chairman stated. “As a regulator, our main job is to look at investor confidence plus investor protection. And indirectly your job facilitates that as well.”

The Chairman emphasized that the overall reputation of the Sri Lankan capital market depends on the professional judgment and performance of Corporate Finance Advisors, as investors make decisions based on their assessments and recommendations.

Senior Prof. D.B.P.H. Dissabandara

Reinforcing this message, Mr. Rajeeva Bandaranaike, Chief Executive Officer, CSE emphasized the importance of collaboration in improving market efficiency. “The objective is to completely revamp and improve the overall listing experience for companies and issuers,” he stated. “This is a journey that we need to go together with the community. We cannot do this alone.”

He also noted the complexity of public listings compared to bank financing, explaining that heightened scrutiny is necessary when dealing with public money. “At the end of the day, if the prospectus is not clean and accurate, we’re going to face problems. We don’t want companies going into the watchlist after one or two months of listing.”

Building on this framework, Ms. Kanishka Munasinghe, Vice President, Listing, CSE highlighted critical gaps in recent listing applications, particularly regarding litigation disclosure and legal due diligence. The CSE has expanded its disclosure requirements to cover not just financial impact but also operational continuity and licensing implications.

Continue Reading

Business

nVentures leads US $200K seed round into Flash Health to scale cashless outpatient care in Sri Lanka

Published

on

Flash Health, a Sri Lankan healthtech startup building cashless, on-demand outpatient care, has raised a US $200,000 seed round led by nVentures, with participation from angel investors across Sri Lanka, Singapore, and the United States.

The funding comes as Flash Health expands its footprint across insurers, large employers, and healthcare providers, positioning itself as one of the country’s most widely adopted digital outpatient platforms addressing everyday healthcare needs.

At the core of Flash Health’s offering is Cashless OPD, which allows employees and policyholders to access doctor consultations, medicines, diagnostics, and telemedicine services without paying out of pocket, removing upfront payments and simplifying access to address a long-standing friction point in everyday healthcare across emerging markets. The platform’s approach has also received global recognition, with Cashless OPD winning at the World Summit Awards, an UN-backed platform recognising startups advancing the Sustainable Development Goals, selected from over 900 applications across 143 countries. Commenting on the investment, Chalinda Abeykoon, Managing Partner at nVentures, said, “We first met Arshad and the Flash Health team in late 2023 and were immediately struck by their ethos, attention to detail, and culture of excellence. As we worked with the team to fine-tune their product roadmap and execution, we saw a team that listens, iterates, and delivers. Flash Health is now operating at real scale, which made this a clear investment decision for us.”

Flash Health’s growth has been driven by partnerships with leading insurance providers, including AIA, HNB Assurance, Janashakthi Insurance, and Union Assurance, enabling policyholders to access services such as medicine delivery, home lab testing, telemedicine consultations, and wellness incentives through integrated digital workflows.

Continue Reading

Trending